Erasca

An open book with pages turning on a wooden table set
Biotech

Erasca looks to partner off late-stage melanoma asset

The asset, which Erasca picked up from Novartis for $20 million, would be the first targeted therapy in NRASm melanoma if it were to make it to market.
Gabrielle Masson May 13, 2025 10:38am
layoffs cut staff reduction workforce

Erasca lays off 18%, swaps out KRAS program for fresh options

May 17, 2024 5:30am
eraser pencil mistake write cut pen scrub out

Erasca erases part of pipeline after revealing mixed cancer data

Jun 6, 2023 10:00am
wheel driver driving drive steering wheel

Erasca slides a Novartis melanoma med into pipeline for $20M

Dec 9, 2022 10:50am
cancer newspaper

Erasca nabs $300M IPO to attack cancer's favorite pathway

Jul 16, 2021 10:10am